NM_032638.5(GATA2):c.782G>A (p.Ser261Asn) AND multiple conditions

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: May 11, 2023
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV003794011.2

Allele description [Variation Report for NM_032638.5(GATA2):c.782G>A (p.Ser261Asn)]

NM_032638.5(GATA2):c.782G>A (p.Ser261Asn)

Gene:

GATA2:GATA binding protein 2 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

3q21.3

Genomic location:

Preferred name:

NM_032638.5(GATA2):c.782G>A (p.Ser261Asn)

HGVS:

NC_000003.12:g.128485816C>T
NG_029334.1:g.12372G>A
NM_001145661.2:c.782G>A
NM_001145662.1:c.782G>A
NM_032638.5:c.782G>AMANE SELECT
NP_001139133.1:p.Ser261Asn
NP_001139133.1:p.Ser261Asn
NP_001139134.1:p.Ser261Asn
NP_116027.2:p.Ser261Asn
NP_116027.2:p.Ser261Asn
LRG_295t1:c.782G>A
LRG_295t2:c.782G>A
LRG_295:g.12372G>A
LRG_295p1:p.Ser261Asn
LRG_295p2:p.Ser261Asn
NC_000003.11:g.128204659C>T
NM_001145661.1:c.782G>A
NM_032638.4:c.782G>A

Protein change:

S261N

Molecular consequence:

NM_001145661.2:c.782G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001145662.1:c.782G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_032638.5:c.782G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Deafness-lymphedema-leukemia syndrome
Synonyms:: Lymphedema, primary, with myelodysplasia; Emberger syndrome
Identifiers:: MONDO: MONDO:0013540; MedGen: C3279664; Orphanet: 3226; OMIM: 614038

Name:: Monocytopenia with susceptibility to infections
Synonyms:: MONOCYTOPENIA AND MYCOBACTERIAL INFECTION SYNDROME; MONOCYTOPENIA WITH SUSCEPTIBILITY TO MYCOBACTERIAL, FUNGAL, AND PAPILLOMAVIRUS INFECTIONS AND MYELODYSPLASIA; COMBINED IMMUNODEFICIENCY WITH SUSCEPTIBILITY TO MYCOBACTERIAL, VIRAL, AND FUNGAL INFECTIONS; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0013607; MedGen: C3280030; Orphanet: 228423; OMIM: 614172

Recent activity

Clear Turn Off Turn On

Cercocebus atys
Cercocebus atys
Cercocebus atys RefSeq Genome sequencing

BioProject
BioProject Links for Nucleotide (Select 778170589) (1)
BioProject
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif 3 [Homo sapiens]
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif 3 [Homo sapiens]
Gene ID:9508

Gene
Gene Links for GEO Profiles (Select 34507009) (1)
Gene
c-MYC depletion effect on carcinoma cell lines
c-MYC depletion effect on carcinoma cell lines
Accession: GDS2526

GEO DataSets

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV004582151	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (May 11, 2023)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV004582151

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(May 11, 2023)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004582151.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GATA2 protein function. This variant has not been reported in the literature in individuals affected with GATA2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 261 of the GATA2 protein (p.Ser261Asn).

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine